Cognitive Impairment

1
Pipeline Programs
4
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

3 companies ranked by most advanced pipeline stage

E
EisaiChina - Liaoning
1 program
1
AriceptPhase 21 trial
Active Trials
NCT00103948Completed165Est. Feb 2007
T-Therapeutics
T-TherapeuticsUK - Cambridge
1 program
1. cognitive stimulationN/A1 trial
Active Trials
NCT06662474Not Yet RecruitingEst. Dec 2026
Alliance Pharmaceuticals
1 program
Cognitive AssessmentN/A1 trial
Active Trials
NCT03382444Completed19Est. Sep 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
EisaiAricept
T-Therapeutics1. cognitive stimulation
Alliance PharmaceuticalsCognitive Assessment

Clinical Trials (3)

Total enrollment: 184 patients across 3 trials

NCT00103948EisaiAricept

The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment

Start: Feb 2005Est. completion: Feb 2007165 patients
Phase 2Completed
NCT06662474T-Therapeutics1. cognitive stimulation

Cognitive Impairment in Treated Breast Cancer Survivors: Possible Approaches

Start: Nov 2024Est. completion: Dec 2026
N/ANot Yet Recruiting
NCT03382444Alliance PharmaceuticalsCognitive Assessment

The Kidney and The Brain Study - Assessment of Cognitive Impairment in Advanced CKD

Start: Feb 2018Est. completion: Sep 201919 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

4 companies competing in this space